stockportfolio.pro
Stocks / NVS vs TMO
NVS vs TMO
Novartis AG and Thermo Fisher Scientific Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Novartis AG (NVS) | Thermo Fisher Scientific Inc. (TMO) | |
|---|---|---|
| Market cap | $290.6B | $176.0B |
| Revenue (latest FY) | $56.67B | $44.56B |
| Net income (latest FY) | $13.98B | $6.70B |
| Revenue growth (5y CAGR) | 9.3% | 6.7% |
| Net margin | 24.7% | 15.0% |
| Return on equity | 30.3% | 12.6% |
| P/E ratio | 21.8 | 26.0 |
| Dividend yield | 3.2% | 0.4% |
| Profitable years (of last 10) | 4 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NVS — free Open TMO — freeFrequently asked questions
Which is bigger, NVS or TMO?
Novartis AG is larger by market capitalization — $290.6B versus $176.0B.
Which grows faster, NVS or TMO?
Over the last five fiscal years, Novartis AG grew revenue faster — 9.3%/yr versus 6.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.